Table 4.
Effects of genetic mutations, type of surgery, location of involvement, and the degree of histological differentiation.
| Progression |
|||
|---|---|---|---|
| No | Yes | P | |
| KRAS | |||
| Wild | 23 (52.27%) | 26 (34.21%) | 0.05 |
| Mutant | 21 (47.73%) | 50 (65.79%) | |
| NRAS | |||
| Wild | 21 (80.77%) | 26 (54.17%) | 0.023 |
| Mutant | 5 (19.23%) | 22 (45.83%) | |
| BRAF | |||
| Wild | 21 (70%) | 32 (56.1%) | 0.208 |
| Mutant | 9 (30%) | 25 (43.9%) | |
| Operation | |||
| Elective | 136 (87.18%) | 73 (83.91%) | 0.481 |
| Urgent | 20 (12.82%) | 14 (16.09%) | |
| Tumor side | |||
| Right | 59 (37.82%) | 34 (39.08%) | 0.846 |
| Left | 97 (62.18%) | 53 (60.92%) | |
| Differentiation | |||
| Good | 10 (6.41%) | 6 (6.9%) | 0.002 |
| Moderate | 67 (42.95%) | 18 (20.69%) | |
| Poor | 79 (50.64%) | 63 (72.41%) | |
| Operation to chemotherapy (days) | 44.57 ± 23.51 | 48.8 ± 21.53 | 0.022 |
| Total lymph nodes (n) | 14.8 ± 5.9 | 15.9 ± 5.7 | 0.143 |
| Metastatic lymph nodes (n) | 2.5 ± 3 | 3.3 ± 2.88 | 0.0001 |